Last reviewed · How we verify

NCT03684187

Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis

Terminated NA Last updated 25 May 2025
What this trial tests

NA trial testing Mindfulness Based Intervention in Primary Biliary Cholangitis in 6 participants. Terminated before completion.

Timeline
19 November 2018
Primary endpoint
26 June 2019
17 April 2023

Quick facts

Lead sponsorYale University
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment6
Start date19 November 2018
Primary completion26 June 2019
Estimated completion17 April 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

Adults 18 to 75, any sex, with Primary Biliary Cholangitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the efficacy of mindfulness-based intervention (MBI) intervention in the treatment of moderate or severe fatigue in patients with primary biliary cholangitis (PBC).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Clinical Updates in Primary Biliary Cholangitis: Trends, Epidemiology, Diagnostics, and New Therapeutic Approaches.
    Galoosian A, Hanlon C, Zhang J, Holt EW, et al · · 2020 · cited 33× · PMID 32274345 · DOI 10.14218/jcth.2019.00049

Verify or expand the search:

Other trials of Mindfulness Based Intervention

Trials testing the same drug.

Other recruiting trials for Primary Biliary Cholangitis

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03684187.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing